RxDoctor Payments Data

Morgan Momyer

Family · Florence, SCNPI 1447787403

Payments from drug & device makers

$1,592in general payments, 2019–2025

Across 18 payments — averaging $88.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$255
  • AstraZeneca$243
  • Novo Nordisk$197
  • GSK$121
  • Idorsia Pharmaceuticals US Inc$117
  • Insmed, Inc.$116
  • plus $541 from 7 others

What the payments were for

  • Food & beverage$1,592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,592 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$16,962
Medicare patients
55
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide64$164,695
AuryxiaFerric Citrate40$96,123
Sevelamer Carbonate142$16,706
Lanthanum Carbonate23$14,285
Calcium Acetate26$3,261
Midodrine Hcl29$1,927
Megestrol Acetate14$640
Hydralazine Hcl28$320
Atorvastatin Calcium33$207
Metoprolol Tartrate27$170
Nifedipine ErNifedipine14$167
Pantoprazole Sodium32$151
Amlodipine Besylate31$144
Losartan Potassium20$108
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$20$164,69564 claims
Akebia Therapeutics IncAuryxia$100$96,12340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →